Who
Karen Jean Ferrante
Director
Company insider
Files Form 4 as: Director, Cogent Biosciences; Director, MacroGenics; Director, Progenics Pharmaceuticals; Director, Baxalta; Head Res. & Dev. & Chief Med., Eledon Pharmaceuticals.
In numbers
- Trades disclosed
- 93
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 29 Jan 2014
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —759 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —627 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —627 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,901 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,901 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,750 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,750 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —3,750 | filing |
| 18 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —3,750 | filing |
| 1 Apr 2026filed 3 Apr 2026 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —686 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —686 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —643 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —643 at $0.00 | filing |
| 1 Oct 2025filed 3 Oct 2025 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,642 at $0.00 | filing |
| 1 Jul 2025filed 2 Jul 2025 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,314 at $0.00 | filing |
| 4 Jun 2025filed 5 Jun 2025 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,700 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.